These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29727569)

  • 1. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
    Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
    J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
    Hurt DE; Sutton AE; Clardy J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
    Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
    Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
    DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An alternative conformation of the N-terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent.
    Alberti M; Poli G; Broggini L; Sainas S; Rizzi M; Boschi D; Ferraris DM; Martino E; Ricagno S; Tuccinardi T; Lolli ML; Miggiano R
    Acta Crystallogr D Struct Biol; 2024 Jun; 80(Pt 6):386-396. PubMed ID: 38805244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.
    Vyas VK; Variya B; Ghate MD
    Eur J Med Chem; 2014 Jul; 82():385-93. PubMed ID: 24929289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biaryl analogues of teriflunomide as potent DHODH inhibitors.
    Erra M; Moreno I; Sanahuja J; Andrés M; Reinoso RF; Lozoya E; Pizcueta P; Godessart N; Castro-Palomino JC
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7268-72. PubMed ID: 22078215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites.
    Walse B; Dufe VT; Svensson B; Fritzson I; Dahlberg L; Khairoullina A; Wellmar U; Al-Karadaghi S
    Biochemistry; 2008 Aug; 47(34):8929-36. PubMed ID: 18672895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of isoquinolinone DHODH inhibitor isosteres.
    DeRatt LG; Zhang Z; Pietsch EC; Cisar J; Wang A; Wang CY; Tanner A; Shaffer P; Jacoby E; Kazmi F; Shukla N; Philippar U; Attar RM; Edwards JP; Kuduk SD
    Bioorg Med Chem Lett; 2024 Nov; 113():129965. PubMed ID: 39284456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
    Sainas S; Giorgis M; Circosta P; Gaidano V; Bonanni D; Pippione AC; Bagnati R; Passoni A; Qiu Y; Cojocaru CF; Canepa B; Bona A; Rolando B; Mishina M; Ramondetti C; Buccinnà B; Piccinini M; Houshmand M; Cignetti A; Giraudo E; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
    J Med Chem; 2021 May; 64(9):5404-5428. PubMed ID: 33844533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods.
    Higgins WT; Vibhute S; Bennett C; Lindert S
    J Chem Inf Model; 2024 Jan; 64(2):435-448. PubMed ID: 38175956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
    Phillips MA; Lotharius J; Marsh K; White J; Dayan A; White KL; Njoroge JW; El Mazouni F; Lao Y; Kokkonda S; Tomchick DR; Deng X; Laird T; Bhatia SN; March S; Ng CL; Fidock DA; Wittlin S; Lafuente-Monasterio M; Benito FJ; Alonso LM; Martinez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Haselden JN; Louttit J; Cui Y; Sridhar A; Zeeman AM; Kocken C; Sauerwein R; Dechering K; Avery VM; Duffy S; Delves M; Sinden R; Ruecker A; Wickham KS; Rochford R; Gahagen J; Iyer L; Riccio E; Mirsalis J; Bathhurst I; Rueckle T; Ding X; Campo B; Leroy D; Rogers MJ; Rathod PK; Burrows JN; Charman SA
    Sci Transl Med; 2015 Jul; 7(296):296ra111. PubMed ID: 26180101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors.
    Bonomo S; Tosco P; Giorgis M; Lolli M; Fruttero R
    J Mol Model; 2013 Mar; 19(3):1099-107. PubMed ID: 23143678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent human dihydroorotate dehydrogenase inhibitory activity of new quinoline-4-carboxylic acids derived from phenolic aldehydes: Synthesis, cytotoxicity, lipophilicity and molecular docking studies.
    Petrović MM; Roschger C; Chaudary S; Zierer A; Mladenović M; Jakovljević K; Marković V; Botta B; Joksović MD
    Bioorg Chem; 2020 Dec; 105():104373. PubMed ID: 33074120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
    Popova G; Ladds MJGW; Johansson L; Saleh A; Larsson J; Sandberg L; Sahlberg SH; Qian W; Gullberg H; Garg N; Gustavsson AL; Haraldsson M; Lane D; Yngve U; Lain S
    J Med Chem; 2020 Apr; 63(8):3915-3934. PubMed ID: 32212728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
    Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
    Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
    Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
    Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
    Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
    FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
    Cheleski J; Rocha JR; Pinheiro MP; Wiggers HJ; da Silva AB; Nonato MC; Montanari CA
    Eur J Med Chem; 2010 Dec; 45(12):5899-909. PubMed ID: 20965617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.